All Title Author
Keywords Abstract

PLOS ONE  2012 

Inactivation of SLIT2-ROBO1/2 Pathway in Premalignant Lesions of Uterine Cervix: Clinical and Prognostic Significances

DOI: 10.1371/journal.pone.0038342

Full-Text   Cite this paper   Add to My Lib

Abstract:

The SLIT2-ROBO1/2 pathways control diverse biological processes, including growth regulation. To understand the role of SLIT2 and ROBO1/2 in cervical carcinogenesis, firstly their RNA expression profiles were screened in 21 primary uterine cervical carcinoma (CACX) samples and two CACX cell lines. Highly reduced expressions of these genes were evident. Concomitant alterations [deletion/methylation] of the genes were then analyzed in 23 cervical intraepithelial neoplasia (CIN) and 110 CACX samples. In CIN, SLIT2 was deleted in 22% samples compared to 9% for ROBO1 and none for ROBO2, whereas comparable methylation was observed for both SLIT2 (30%) and ROBO1 (22%) followed by ROBO2 (9%). In CACX, alteration of the genes were in the following order: Deletion: ROBO1 (48%) > SLIT2 (35%) > ROBO2 (33%), Methylation: SLIT2 (34%) > ROBO1 (29%) > ROBO2 (26%). Overall alterations of SLIT2 and/or ROBO1 (44%) and SLIT2 and/or ROBO2 (39%) were high in CIN followed by significant increase in stage I/II tumors, suggesting deregulation of these interactions in premalignant lesions and early invasive tumors. Immunohistochemical analysis of SLIT2 and ROBO1/2 in CACX also showed reduced expression concordant with molecular alterations. Alteration of all these genes predicted poor patient outcome. Multiparous (≥5) women with altered SLIT2 and ROBO1 along with advanced tumor stage (III/IV) and early sexual debut (<19 years) had worst prognosis. Our data suggests the importance of abrogation of SLIT2-ROBO1 and SLIT2-ROBO2 interactions in the initiation and progression of CACX and also for early diagnosis and prognosis of the disease.

References

[1]  Murthy NS, Mathew A (1999) Screening for cancer of the uterine cervix and approaches adopted in India. Indian J Cancer 36: 154–162.
[2]  Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153–156.
[3]  Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global Cancer Statistics, 2002. CA Cancer J 4. Clin 55: 74–108.
[4]  Sen U, Sankaranarayanan R, Mandal S, Ramanakumar AV, Parkin DM, et al. (2002) Cancer patterns in eastern India: the first report of the kolkata cancer registry. Int J Cancer 100: 86–91.
[5]  zur Hausen H (2000) Papilloma virus causing cancer: evasion from host cell control in early events in carcinogenesis. J Natl Cancer Inst 91: 690–698.
[6]  Slattery M, Overall JC Jr, Abbott TM, French TK, Robison M, et al. (1989) Sexual activity contraception, genital infections and cervical cancer: Support for a sexually transmitted disease hypothesis. Am J Epidemiol 130: 248–259.
[7]  Lazo PA (1999) The molecular genetics of cervical carcinoma. Br J Cancer 80: 2008–2016.
[8]  Heselmeyer K, Schr?ck E, du Manoir S, Blegen H, Shah K, et al. (1996) Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc Natl Acad Sci USA 93: 479–484.
[9]  Atkin NB (1997) Cytogenetics of carcinoma of the cervix uteri: a review. Cancer Genet Cytogenet 95: 33–39.
[10]  Allen DG, White DJ, Hutchins AM, Scurry JP, Tabrizi SN, et al. (2000) Progressive genetic aberrations detected by comparative genomic hybridization in squamous cell cervical cancer. Br J Cancer 83: 1659–1663.
[11]  Harris CP, Lu XY, Narayan G, Singh B, Murty VV, et al. (2003) Comprehensive molecular cytogenetic characterization of cervical cancer cell lines. Genes Chromosomes Cancer 36: 233–241.
[12]  Singh RK, Indra D, Mitra S, Mondal RK, Basu PS, et al. (2007) Deletions in chromosome 4 differentially associated with the development of cervical cancer: evidence of slit2 as a candidate tumor suppressor gene. Hum Genet 122: 71–81.
[13]  Narayan G, Goparaju C, Arias-Pulido H, Kaufmann AM, Schneider A, et al. (2006) Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression. Molecular Cancer 5: 16.
[14]  Dickinson RE, Duncan WC (2010) The SLIT–ROBO pathway: a regulator of cell function with implications for the reproductive system. Reproduction. DOI:10.1530/REP–10–0017.
[15]  Ghosh S, Ghosh A, Maiti GP, Alam N, Roy A, et al. (2009) Alterations of ROBO1/DUTT1 and ROBO2 loci in early dysplastic lesions of head and neck: clinical and prognostic implications. Hum Genet 125: 189–198.
[16]  Angeloni D, Elst A, Wei MH, van deer Veen AY, Braga EA, et al. (2006) Analysis of a new homozygous deletion in the tumor suppressor region at 3p12.3 reveals two novel intronic noncoding RNA genes. Genes Chromosome Cancer 45: 676–691.
[17]  Mitra S, Mazumder D, Basu PS, Mondal RK, Roy A, et al. (2010) Amplification of CyclinL1 in uterine cervical carcinoma has prognostic implications. Mol Carcinog 49: 935–943.
[18]  Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402–408.
[19]  Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative CT method. Nat Protoc 3: 1101–1108.
[20]  Dasgupta S, Mukherjee N, Roy S, Roy A, Sengupta A, et al. (2002) Mapping of candidate tumor suppressor genes’ loci on human chromosome 3 in head and neck squamous cell carcinoma of an Indian patient population. Oral Oncol 38: 6–15.
[21]  Sambrook J, Fritsch EF, Maniatis T (1989) NY Cold Spring Harbor, Cold Spring Harbor Laboratory NY. Molecular Cloning: A Laboratory Manual, 2nd ed.
[22]  Loginov VI, Maliukova AV, Seregin IuA, Khodyrev DS, Kazubskaia TP, et al. (2004) Methylation of the promoter region of the RASSF1A candidate tumor suppressor gene in primary epithelial tumors. Mol Biol (Mosk) 38: 654–667.
[23]  Herman JG, Jeremy R, Graff JR, My?h?nen S, Nelkin BD, et al. (1996) Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands Proc. Natl. Acad. Sci.U.S.A 93: 9821–9826.
[24]  Ichimura K, Bolin MB, Goike HM, Schmidt EE, Moshref A, et al. (2000) Deregulation of p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 60: 417–424.
[25]  Perrone F, Suardi S, Pastore E, Casieri P, Orsenigo M, et al. (2006) Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res 12: 6643–6651.
[26]  Singh RK, Dasgupta S, Bhattacharya N, Chunder N, Mondal R, et al. (2005) Deletion in chromosome 11 and Bcl-1/CyclinD1 alterations are independently associated with the development of uterine cervical carcinoma. J Cancer Res Clin Oncol 131: 395–406.
[27]  Zabarovsky ER, Lerman MI, Minna JD (2002) Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 21: 6915–6935.
[28]  Dallol A, Forgacs E, Martinez A, Sekido Y, Walker R, et al. (2002a) Tumour specific promoter region methylation of the human homologue of the Drosophila Roundabout gene DUTT1 (ROBO1) in human cancers. Oncogene 21: 3020–3028.
[29]  Dallol A, Fernandes Da Silva N, Viacava P, Minna JD, Bieche I, et al. (2002b) SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers. Cancer Res 62: 5874–5880.
[30]  Dallol A, Krex D, Hesson L, Eng C, Maher ER, et al. (2003a) Frequent epigenetic inactivation of the SLIT2 gene in gliomas. Oncogene 22: 4611–4616.
[31]  Zheng D, Liu BB, Liu YK, Kang XN, Sun L, et al. (2009) [Analysis of the expression of Slit/Robo genes and the methylation status of their promoters in the hepatocellular carcinoma cell lines] [Article in Chinese] Zhonghua Gan Zang Bing Za Zhi 17: 198–202.
[32]  Yiin JJ, Hu B, Jarzynka MJ, Feng H, Liu KW, et al. (2009) Slit2 inhibits glioma cell invasion in the brain by suppression of Cdc42 activity. Neuro Oncol 11: 779–789.
[33]  Tseng RC, Lee SH, Hsu HS, Chen BH, Tsai WC, et al. (2010) SLIT2 Attenuation during Lung cancer progression deregulates β-Catenin and E-Cadherin and associates with poor prognosis. Cancer Res 70: 543–551.
[34]  Latil A, Chene L, Cochant-Priollet B, Mangin P, Fournier G, et al. (2003) Quantification of expression of netrins, slits and their receptors in human prostate tumors. Int J Cancer 103: 306–315.
[35]  Bièche I, Lerebours F, Tozlu S, Espie M, Marty M, et al. (2004) Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res 10: 6789–6795.
[36]  Martinez A, Fullwood P, Kondo K, Kishida T, Yao M, et al. (2000) Role of chromosome 3p12–p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis. J Clin Pathol: Mol Pathol 53: 137–144.
[37]  Martinez A, Walker RA, Shaw JA, Dearing SJ, Maher ER, et al. (2001) Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features. J Clin Pathol: Mol Pathol 54: 300–306.
[38]  Dallol A, Morton D, Maher ED, Latif F, et al. (2003b) SLIT2 axon guidance molecule is frequently inactivated in colorectal cancer and suppresses growth of colorectal carcinoma cells. Cancer Res 63: 1054–1058.
[39]  Astuti D, Da Silva NF, Dallol A, Gentle D, Martinsson T, et al. (2004) SLIT2 promoter methylation analysis in nerublastoma, Wilm’s tumor and renal cell carcinoma. Br J Cancer 90: 515–521.
[40]  Dunwell TL, Dickinson RE, Stankovic T, Dallol A, Weston V, et al. (2009) Frequent epigenetic inactivation of the SLIT2 gene in chronic and acute lymphocytic leukemia. Epigenetics 4: 265–269.
[41]  Sundaresan V, Chung G, Heppell-Parton A, Xiong J, Grundy C, et al. (1998) Homozygous deletions at 3p12 in breast and lung cancer. Oncogene 17: 1723–1729.
[42]  Hampton GM, Larson AA, Baergen RN, Sommers RL, Kern S, et al. (1996) Simultaneous assessment of loss of heterozygosity at multiple microsatellite loci using semi-automated fluorescence-based detection: subregional mapping of chromosome 4 in cervical carcinoma. Proc Natl Acad Sci USA 93: 6704–6709.
[43]  Li LC, Shiina H, Deguchi M, Zhao H, Okino ST, et al. (2004) Age-dependent methylation of ESR1 gene in prostate cancer. Biochem Biophys Res Commun 321: 455–461.
[44]  Yuasa Y, Nagasaki H, Akiyama Y, Sakai H, Nakajima T, et al. (2005) Relationship between CDX2 gene methylation and dietary factors in gastric cancer patients. Carcinogenesis 26: 193–200.
[45]  Prasad A, Paruchuri V, Preet A, Latif F, Ganju RK (2008) Slit-2 induces a tumor-suppressive effect by regulating β-Catenin in breast cancer cells. J Biol Chem 283: 26624–26633.

Full-Text

comments powered by Disqus